S&P 500   3,891.93 (-0.25%)
DOW   31,516.72 (-0.06%)
QQQ   320.67 (-0.90%)
AAPL   125.78 (-1.57%)
MSFT   234.94 (-0.84%)
FB   263.97 (-0.35%)
GOOGL   2,082.67 (+0.63%)
TSLA   694.42 (-3.34%)
AMZN   3,131.24 (-0.47%)
NVDA   543.64 (-1.81%)
BABA   238.00 (-1.53%)
CGC   34.89 (+0.46%)
GE   13.05 (-0.46%)
MU   92.02 (-2.89%)
NIO   43.56 (-12.46%)
AMD   85.60 (-0.91%)
T   28.34 (+0.89%)
F   12.68 (+5.84%)
ACB   11.09 (+0.45%)
DIS   194.59 (-0.20%)
BA   223.96 (-0.19%)
NFLX   551.73 (+0.20%)
BAC   35.66 (-0.36%)
S&P 500   3,891.93 (-0.25%)
DOW   31,516.72 (-0.06%)
QQQ   320.67 (-0.90%)
AAPL   125.78 (-1.57%)
MSFT   234.94 (-0.84%)
FB   263.97 (-0.35%)
GOOGL   2,082.67 (+0.63%)
TSLA   694.42 (-3.34%)
AMZN   3,131.24 (-0.47%)
NVDA   543.64 (-1.81%)
BABA   238.00 (-1.53%)
CGC   34.89 (+0.46%)
GE   13.05 (-0.46%)
MU   92.02 (-2.89%)
NIO   43.56 (-12.46%)
AMD   85.60 (-0.91%)
T   28.34 (+0.89%)
F   12.68 (+5.84%)
ACB   11.09 (+0.45%)
DIS   194.59 (-0.20%)
BA   223.96 (-0.19%)
NFLX   551.73 (+0.20%)
BAC   35.66 (-0.36%)
S&P 500   3,891.93 (-0.25%)
DOW   31,516.72 (-0.06%)
QQQ   320.67 (-0.90%)
AAPL   125.78 (-1.57%)
MSFT   234.94 (-0.84%)
FB   263.97 (-0.35%)
GOOGL   2,082.67 (+0.63%)
TSLA   694.42 (-3.34%)
AMZN   3,131.24 (-0.47%)
NVDA   543.64 (-1.81%)
BABA   238.00 (-1.53%)
CGC   34.89 (+0.46%)
GE   13.05 (-0.46%)
MU   92.02 (-2.89%)
NIO   43.56 (-12.46%)
AMD   85.60 (-0.91%)
T   28.34 (+0.89%)
F   12.68 (+5.84%)
ACB   11.09 (+0.45%)
DIS   194.59 (-0.20%)
BA   223.96 (-0.19%)
NFLX   551.73 (+0.20%)
BAC   35.66 (-0.36%)
S&P 500   3,891.93 (-0.25%)
DOW   31,516.72 (-0.06%)
QQQ   320.67 (-0.90%)
AAPL   125.78 (-1.57%)
MSFT   234.94 (-0.84%)
FB   263.97 (-0.35%)
GOOGL   2,082.67 (+0.63%)
TSLA   694.42 (-3.34%)
AMZN   3,131.24 (-0.47%)
NVDA   543.64 (-1.81%)
BABA   238.00 (-1.53%)
CGC   34.89 (+0.46%)
GE   13.05 (-0.46%)
MU   92.02 (-2.89%)
NIO   43.56 (-12.46%)
AMD   85.60 (-0.91%)
T   28.34 (+0.89%)
F   12.68 (+5.84%)
ACB   11.09 (+0.45%)
DIS   194.59 (-0.20%)
BA   223.96 (-0.19%)
NFLX   551.73 (+0.20%)
BAC   35.66 (-0.36%)
Log in
ETR:EVT

Evotec SE (EVT.F) Competitors

€32.75
+0.68 (+2.12 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
€32.47
Now: €32.75▼
€33.05
50-Day Range
€28.77
MA: €32.53▼
€37.20
52-Week Range
€17.17
Now: €32.75▼
€43.00
Volume486,169 shs
Average Volume1.36 million shs
Market Capitalization$5.35 billion
P/E Ratio355.98
Dividend YieldN/A
BetaN/A

Competitors

Evotec SE (EVT.F) (ETR:EVT) Vs. MRK, FME, SRT, AFX, MOR, and GXI

Should you be buying EVT stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Evotec SE (EVT.F), including MERCK Kommanditgesellschaft auf Aktien (MRK), Fresenius Medical Care AG & Co. KGaA (FME), Sartorius Aktiengesellschaft (SRT), Carl Zeiss Meditec (AFX), MorphoSys (MOR), and Gerresheimer (GXI).

Evotec SE (EVT.F) vs. MERCK Kommanditgesellschaft auf Aktien Stock

Evotec SE (EVT.F) (ETR:EVT) and MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Profitability

This table compares Evotec SE (EVT.F) and MERCK Kommanditgesellschaft auf Aktien's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evotec SE (EVT.F)N/AN/AN/A
MERCK Kommanditgesellschaft auf AktienN/AN/AN/A

Valuation & Earnings

This table compares Evotec SE (EVT.F) and MERCK Kommanditgesellschaft auf Aktien's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evotec SE (EVT.F)$485.49 million11.03$15.04 million€0.09355.98
MERCK Kommanditgesellschaft auf Aktien$17.32 billion1.02$554.71 million€4.2931.84

MERCK Kommanditgesellschaft auf Aktien has higher revenue and earnings than Evotec SE (EVT.F). MERCK Kommanditgesellschaft auf Aktien is trading at a lower price-to-earnings ratio than Evotec SE (EVT.F), indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Evotec SE (EVT.F) and MERCK Kommanditgesellschaft auf Aktien, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evotec SE (EVT.F)02302.60
MERCK Kommanditgesellschaft auf Aktien0000N/A

Evotec SE (EVT.F) presently has a consensus price target of €32.60, indicating a potential downside of 0.46%. Given Evotec SE (EVT.F)'s higher possible upside, equities research analysts plainly believe Evotec SE (EVT.F) is more favorable than MERCK Kommanditgesellschaft auf Aktien.

Summary

Evotec SE (EVT.F) beats MERCK Kommanditgesellschaft auf Aktien on 4 of the 7 factors compared between the two stocks.

Evotec SE (EVT.F) vs. Fresenius Medical Care AG & Co. KGaA Stock

Fresenius Medical Care AG & Co. KGaA (ETR:FME) and Evotec SE (EVT.F) (ETR:EVT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Fresenius Medical Care AG & Co. KGaA and Evotec SE (EVT.F), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius Medical Care AG & Co. KGaA17602.36
Evotec SE (EVT.F)02302.60

Fresenius Medical Care AG & Co. KGaA presently has a consensus target price of €69.85, indicating a potential upside of 20.06%. Evotec SE (EVT.F) has a consensus target price of €32.60, indicating a potential downside of 0.46%. Given Fresenius Medical Care AG & Co. KGaA's higher probable upside, equities analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Evotec SE (EVT.F).

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Evotec SE (EVT.F)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius Medical Care AG & Co. KGaAN/AN/AN/A
Evotec SE (EVT.F)N/AN/AN/A

Valuation & Earnings

This table compares Fresenius Medical Care AG & Co. KGaA and Evotec SE (EVT.F)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$17.86 billion0.95$1.16 billion€3.9614.69
Evotec SE (EVT.F)$485.49 million11.03$15.04 million€0.09355.98

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Evotec SE (EVT.F). Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Evotec SE (EVT.F), indicating that it is currently the more affordable of the two stocks.

Summary

Fresenius Medical Care AG & Co. KGaA beats Evotec SE (EVT.F) on 5 of the 8 factors compared between the two stocks.

Evotec SE (EVT.F) vs. Sartorius Aktiengesellschaft Stock

Sartorius Aktiengesellschaft (ETR:SRT) and Evotec SE (EVT.F) (ETR:EVT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Sartorius Aktiengesellschaft and Evotec SE (EVT.F), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sartorius Aktiengesellschaft0000N/A
Evotec SE (EVT.F)02302.60

Evotec SE (EVT.F) has a consensus target price of €32.60, suggesting a potential downside of 0.46%. Given Evotec SE (EVT.F)'s higher possible upside, analysts clearly believe Evotec SE (EVT.F) is more favorable than Sartorius Aktiengesellschaft.

Valuation & Earnings

This table compares Sartorius Aktiengesellschaft and Evotec SE (EVT.F)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sartorius Aktiengesellschaft$2.34 billion5.79$113.25 million€3.31119.37
Evotec SE (EVT.F)$485.49 million11.03$15.04 million€0.09355.98

Sartorius Aktiengesellschaft has higher revenue and earnings than Evotec SE (EVT.F). Sartorius Aktiengesellschaft is trading at a lower price-to-earnings ratio than Evotec SE (EVT.F), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sartorius Aktiengesellschaft and Evotec SE (EVT.F)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sartorius AktiengesellschaftN/AN/AN/A
Evotec SE (EVT.F)N/AN/AN/A

Summary

Evotec SE (EVT.F) beats Sartorius Aktiengesellschaft on 4 of the 7 factors compared between the two stocks.

Evotec SE (EVT.F) vs. Carl Zeiss Meditec Stock

Evotec SE (EVT.F) (ETR:EVT) and Carl Zeiss Meditec (ETR:AFX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Earnings and Valuation

This table compares Evotec SE (EVT.F) and Carl Zeiss Meditec's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evotec SE (EVT.F)$485.49 million11.03$15.04 million€0.09355.98
Carl Zeiss Meditec$1.33 billion8.43$130.31 million€1.4686.34

Carl Zeiss Meditec has higher revenue and earnings than Evotec SE (EVT.F). Carl Zeiss Meditec is trading at a lower price-to-earnings ratio than Evotec SE (EVT.F), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evotec SE (EVT.F) and Carl Zeiss Meditec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evotec SE (EVT.F)N/AN/AN/A
Carl Zeiss MeditecN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Evotec SE (EVT.F) and Carl Zeiss Meditec, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evotec SE (EVT.F)02302.60
Carl Zeiss Meditec25101.88

Evotec SE (EVT.F) currently has a consensus target price of €32.60, indicating a potential downside of 0.46%. Carl Zeiss Meditec has a consensus target price of €114.14, indicating a potential downside of 9.27%. Given Evotec SE (EVT.F)'s stronger consensus rating and higher possible upside, equities analysts clearly believe Evotec SE (EVT.F) is more favorable than Carl Zeiss Meditec.

Summary

Evotec SE (EVT.F) beats Carl Zeiss Meditec on 5 of the 8 factors compared between the two stocks.

Evotec SE (EVT.F) vs. MorphoSys Stock

MorphoSys (ETR:MOR) and Evotec SE (EVT.F) (ETR:EVT) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for MorphoSys and Evotec SE (EVT.F), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MorphoSys05402.44
Evotec SE (EVT.F)02302.60

MorphoSys presently has a consensus price target of €118.67, suggesting a potential upside of 38.73%. Evotec SE (EVT.F) has a consensus price target of €32.60, suggesting a potential downside of 0.46%. Given MorphoSys' higher probable upside, equities analysts plainly believe MorphoSys is more favorable than Evotec SE (EVT.F).

Profitability

This table compares MorphoSys and Evotec SE (EVT.F)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphoSysN/AN/AN/A
Evotec SE (EVT.F)N/AN/AN/A

Valuation and Earnings

This table compares MorphoSys and Evotec SE (EVT.F)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$302.73 million9.25$64.76 million€1.9843.25
Evotec SE (EVT.F)$485.49 million11.03$15.04 million€0.09355.98

MorphoSys has higher earnings, but lower revenue than Evotec SE (EVT.F). MorphoSys is trading at a lower price-to-earnings ratio than Evotec SE (EVT.F), indicating that it is currently the more affordable of the two stocks.

Evotec SE (EVT.F) vs. Gerresheimer Stock

Gerresheimer (ETR:GXI) and Evotec SE (EVT.F) (ETR:EVT) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Profitability

This table compares Gerresheimer and Evotec SE (EVT.F)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GerresheimerN/AN/AN/A
Evotec SE (EVT.F)N/AN/AN/A

Valuation & Earnings

This table compares Gerresheimer and Evotec SE (EVT.F)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gerresheimer$1.42 billion1.94$88.55 million€2.8231.08
Evotec SE (EVT.F)$485.49 million11.03$15.04 million€0.09355.98

Gerresheimer has higher revenue and earnings than Evotec SE (EVT.F). Gerresheimer is trading at a lower price-to-earnings ratio than Evotec SE (EVT.F), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gerresheimer and Evotec SE (EVT.F), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gerresheimer31402.13
Evotec SE (EVT.F)02302.60

Gerresheimer currently has a consensus price target of €100.87, suggesting a potential upside of 15.08%. Evotec SE (EVT.F) has a consensus price target of €32.60, suggesting a potential downside of 0.46%. Given Gerresheimer's higher possible upside, analysts plainly believe Gerresheimer is more favorable than Evotec SE (EVT.F).

Summary

Gerresheimer beats Evotec SE (EVT.F) on 5 of the 8 factors compared between the two stocks.


Evotec SE (EVT.F) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MRK
MERCK Kommanditgesellschaft auf Aktien
1.0$136.65+1.5%$17.66 billion$17.32 billion31.84Upcoming Earnings
High Trading Volume
Fresenius Medical Care AG & Co. KGaA logo
FME
Fresenius Medical Care AG & Co. KGaA
1.8$58.18+1.4%$17.04 billion$17.86 billion14.69Analyst Report
News Coverage
Sartorius Aktiengesellschaft logo
SRT
Sartorius Aktiengesellschaft
0.6$395.00+0.5%$13.52 billion$2.34 billion119.37High Trading Volume
Carl Zeiss Meditec logo
AFX
Carl Zeiss Meditec
1.0$125.80+1.2%$11.25 billion$1.33 billion86.34
MorphoSys logo
MOR
MorphoSys
1.4$85.54+2.5%$2.80 billion$302.73 million43.25Analyst Report
News Coverage
Gerresheimer logo
GXI
Gerresheimer
1.5$87.65+2.3%$2.75 billion$1.42 billion31.08
Stratec logo
SBS
Stratec
1.0$119.20+0.8%$1.44 billion$242.39 million63.64
RHÖN-KLINIKUM Aktiengesellschaft logo
RHK
RHÖN-KLINIKUM Aktiengesellschaft
1.1$15.88+0.6%$1.06 billion$1.54 billion134.58
Biotest Aktiengesellschaft logo
BIO
Biotest Aktiengesellschaft
0.5$30.80+1.3%$609.40 million$465.80 million-38.36
Drägerwerk AG & Co. KGaA logo
DRW3
Drägerwerk AG & Co. KGaA
1.2$63.60+0.5%$546.96 million$3.17 billion45.30
Medigene logo
MDG1
Medigene
0.5$4.10+6.6%$100.58 million$8.57 million-4.39Gap Down
AEGON logo
AGN
AEGON
0.5N/AN/A$0.00N/A0.00Gap Down
AMS
American Shared Hospital Services
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Down
Bayer Aktiengesellschaft logo
BAYN
Bayer Aktiengesellschaft
1.3$52.34+4.2%$0.00N/A0.00High Trading Volume
DIA
DiaSorin S.p.A. (DIA.MI)
0.6N/AN/A$0.00N/A0.00Gap Down
Essilor International Société Anonyme logo
EI
Essilor International Société Anonyme
0.5$126.85+0.0%$0.00N/A0.00
Fresenius SE & Co. KGaA logo
FRE
Fresenius SE & Co. KGaA
1.5$35.93+1.4%$0.00N/A0.00Analyst Report
High Trading Volume
GNFT
Genfit
0.5$4.30+0.5%$0.00N/A0.00High Trading Volume
MERCK Kommanditgesellschaft auf Aktien (MRK.F) logo
MRK
MERCK Kommanditgesellschaft auf Aktien (MRK.F)
0.7$136.65+1.5%$0.00N/A0.00High Trading Volume
Novan logo
NOVN
Novan
1.1N/AN/A$0.00N/A0.00Gap Down
Sanofi logo
SAN
Sanofi
1.3$76.42+0.8%$0.00N/A0.00Analyst Report
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$429.40+0.9%$0.00N/A0.00High Trading Volume
Sartorius Stedim Biotech logo
DIM
Sartorius Stedim Biotech
0.8$365.20+0.9%$0.00N/A0.00High Trading Volume
STADA Arzneimittel Aktiengesellschaft logo
SAZ
STADA Arzneimittel Aktiengesellschaft
0.4$80.40+0.0%$0.00N/A0.00
TEV
Teva Pharmaceutical Industries
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 3/2/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.